Credevo conducted a feasibility on AML (Acute Myeloid Leukemia) and we received a great response from Investigator/Sites.
The study was Phase 1 & Phase 2, Interventional, Multi-center, Randomised, Open label, Single-arm, Multiple ascending dose with patient criteria of Acute Myeloid Leukemia non eligible for intensive chemotherapy as first-line, second-line, or third-line of treatment.
Sites targeted for this feasibility assessment were medical centers and sites located in Canada.
Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cells with Symptoms like feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.
Get the Report
Would you like to contact these investigators and assess feasibility with them for your clinical trial?
Please provide your email below to get detailed feasibility report on AML (Acute Myeloid Leukemia) in Canada.
Share this report
Recommend this report to your friends and colleagues, who would be benefited with this readily available feasibility report.